Canada: J&J’s Janssen Denied Data Protection Rights For Ketamine Analog Spravato In Canada, Court Rules ‘Not An Innovative Drug’
Cannabis Law Report
AUGUST 10, 2021
The Federal Court of Appeals in Canada ratified a Ministry of Health decision to refuse to provide J anssen Pharmaceuticals, a subsidiary of Johnson and Johnson (NYSE: JNJ ), data protection for Spravato, a ketamine analog approved for depression. What Is Data Protection And Why Is It Important? and Canada. What Happened?
Let's personalize your content